<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04715126</url>
  </required_header>
  <id_info>
    <org_study_id>EB/200401/OXYJUN/AH</org_study_id>
    <nct_id>NCT04715126</nct_id>
  </id_info>
  <brief_title>Evaluate Efficacy of Oxyjun on Cardiovascular Health in Healthy Individuals.</brief_title>
  <official_title>A Randomized, Placebo-controlled, Blinded Study to Evaluate Efficacy of Oxyjun on Cardiovascular Health in Healthy Individuals.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vedic Lifesciences Pvt. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vedic Lifesciences Pvt. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Terminalia arjuna, commonly known as arjuna, that belongs to the family of Combretaceae. Most&#xD;
      clinical and experimental studies for Terminalia arjuna, have suggested that the crude drug&#xD;
      possesses anti-ischemic, antioxidant, hypolipidemic, and antiatherogenic activities.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 11, 2021</start_date>
  <completion_date type="Actual">September 2, 2021</completion_date>
  <primary_completion_date type="Actual">September 2, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricle ejection fraction</measure>
    <time_frame>Day 0 to Day 56</time_frame>
    <description>1. To evaluate the effect of 8-week consumption of Oxyjun on cardiac pumping capacity of study participants as evaluated by Left ventricle ejection fraction (LVEF).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early filling (E) and the atrial phase (A) will be calculated at rest and the E/A ratio</measure>
    <time_frame>Day 0 to Day 56</time_frame>
    <description>Reduction in myocardial stress of study participants as evaluated by decrease in E/A ratio at the end of week 8 (day 56) from baseline as compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial stress</measure>
    <time_frame>Day 0 to Day 56</time_frame>
    <description>Decline in myocardial stress of study participants as assessed by decrease in rate pressure product at the end of week 8 (day 56) from baseline (day 0) as compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue severity scale</measure>
    <time_frame>Day 0, Day 28, day 56</time_frame>
    <description>Reduction in fatigue of study participants as assessed by decrease in Fatigue severity scale at week 4 (day 28), and week 8 (day 56) from baseline (day 0) as compared to placebo.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Cardiovascular Health</condition>
  <arm_group>
    <arm_group_label>Oxyjun (Extract of Terminilia Arjuna).</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Microcrystalline cellulose)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oxyjun</intervention_name>
    <description>One capsule to be taken after breakfast with water.</description>
    <arm_group_label>Oxyjun (Extract of Terminilia Arjuna).</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One capsule to be taken after breakfast with water.</description>
    <arm_group_label>Placebo (Microcrystalline cellulose)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Participant of either sex, aged ≥ 30 to ≤ 70 years at the time of screening&#xD;
             (completed). 2. Participants with normal to high normal blood pressure (BP) [systolic&#xD;
             BP ≥ 120 and ≤ 139 mm Hg and/or diastolic BP ≥ 80 and ≤ 89 mm Hg] as defined by &quot;The&#xD;
             Task Force for the management of arterial hypertension of the European Society of&#xD;
             Cardiology (ESC) and the European Society of Hypertension (ESH)&quot;. 3. Participants with&#xD;
             normal to mildly deranged 'Left ventricular ejection' as per as per American College&#xD;
             of Cardiology: LVEF ≥ 39 and ≤ 55%. 4. BMI ≥ 25 to ≤ 34.9 kg/m2 5. Normal level of&#xD;
             Aspartate transaminase (AST) and Alanine transaminase (ALT) as specified by reference&#xD;
             range of College of American Pathologists certified laboratory. 6. Normal level of&#xD;
             Creatinine as specified by reference range of College of American Pathologists&#xD;
             certified laboratory. 7. Participants must have demonstrated their willingness to&#xD;
             participate in the study and comply with the study procedures and required visits. 8.&#xD;
             Willing to abstain from caffeine, alcohol and related products consumption 12 hours&#xD;
             prior to study visits. 9. Those having the ability to understand and sign a written&#xD;
             informed consent form, which must be completed prior to study specific requirements&#xD;
             being performed. 10. Must be literate and have the ability to complete the study-based&#xD;
             questionnaires and requirements. 11. Female participants of childbearing age must be&#xD;
             willing to use the accepted methods of contraception during the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Systolic BP ≥140 mm Hg and/ or Diastolic BP ≥ 90 mm Hg. 2. Fasting blood sugar ≥ 126&#xD;
             mg/dL 3. Presence of any unstable, acutely symptomatic, or life-limiting illness. 4.&#xD;
             History or presence of clinically significant renal, hepatic, endocrine, biliary,&#xD;
             gastrointestinal, pancreatic or neurologic disorders that, in the judgment of the&#xD;
             investigator, would interfere with the participant's ability to provide informed&#xD;
             consent, comply with the study protocol (that might confound the interpretation of the&#xD;
             study results), or put the participant at undue risk. 5. Using Omega fish oil&#xD;
             supplements, anticonvulsants, Coenzyme Q10, Vitamin K2, proton pump inhibitors, loop&#xD;
             diuretics, anticoagulants, barbiturates, anti-epileptic medications and any herbal&#xD;
             supplements (e.g. flax seeds, chia seeds). 6. Chronic use of anti-inflammatory&#xD;
             medications (≥ 5 tablets/20 days in last 3 months). 7. Individuals having a history of&#xD;
             smoking or currently smoking and also using any form of smokeless tobacco. 8.&#xD;
             High-risk drinking as defined by consumption of 4 or more alcohol containing beverages&#xD;
             on any day or 8 or more alcohol containing beverages per week for women and 5 or more&#xD;
             alcohol containing beverages on any day or 15 or more alcohol containing beverages per&#xD;
             week for men. 9. Binge drinkers as defined by consumption of 4 or more alcohol&#xD;
             containing beverages for women and 5 or more alcohol containing beverages for men&#xD;
             within 2 hours. 10. Abnormal thyroid stimulating hormone (TSH) levels beyond the&#xD;
             defined reference range (&lt;0.4 and &gt; 4.0 IU/ml) 11. Participants unable to walk. 12.&#xD;
             Participants with history of chronic caffeine use. 13. Participants who have any other&#xD;
             disease or condition, or are using any medication, that in the judgment of the&#xD;
             investigator would put him/her at unacceptable risk for participation in the study or&#xD;
             may interfere with evaluations in the study or noncompliance with treatment or visits.&#xD;
             14. Females who are pregnant/planning to be pregnant/lactating or taking any oral&#xD;
             contraceptives. 15. Females undergoing hormone replacement treatments. 16. Menopausal&#xD;
             females having less than 3 years of menopausal history 17. Those unwilling to abstain&#xD;
             from other dietary supplements or medication (e.g. Hepatoprotective agents and other&#xD;
             traditional medicines - Ayurveda, Siddhi, Chinese herbal medicine, Naturopathy). 18.&#xD;
             Have participated in a study of an investigational product 90 days prior to the&#xD;
             screening. 19. Participants with known or suspected hypersensitivity or intolerance to&#xD;
             Investigational product. 20. Participants who are unable to comply with study&#xD;
             requirements. 21. Any clinical signs or symptoms that in the opinion of investigator,&#xD;
             can jeopardize the outcome of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Sanjay Wani, BAMS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shop No.1,VardhmanApartment, Lokmanya Tilak Road,Dahisar west, Mumbai-400068.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr. Awate clinic</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400067</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shree Polyclinic,</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400067</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Rajesh Kewalramani Clinic</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400068</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Wani's Clinic</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400068</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 13, 2021</study_first_submitted>
  <study_first_submitted_qc>January 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

